The data is strongly positive for the CRSwNP + comorbid asthma population, supporting the Phase 3 initiation thesis. Monitor for any regulatory feedback on Phase 3 endpoint discussions.
Price Chart
Executive Summary
Upstream Bio presented positive Phase 2 VIBRANT trial data at ATS 2026, showing verekitug improved asthma control and nasal polyp scores in CRSwNP patients with comorbid asthma, with rapid biomarker reductions and an 83% reduction in rescue therapy need. The data supports planned Phase 3 initiation in Q1 2027, but the company remains a clinical-stage biotech without revenue, and past reports on UPB have shown volatile outcomes.
Key Facts
- Verekitug improved ACQ-6 by -0.9 (95% CI: -1.6 to -0.2; p=0.014) vs placebo in CRSwNP patients with comorbid asthma
- 83% reduction in need for rescue systemic corticosteroids or CRSwNP surgery (p=0.027)
- Rapid and sustained reductions in blood and nasal type 2 inflammatory biomarkers (IL-4, IL-5, IL-13) over 24 weeks
- Company plans to initiate Phase 3 trials in CRSwNP and severe asthma in Q1 2027
- Market cap $495M; 60% of 81 VIBRANT trial participants had comorbid asthma
- Blood eosinophils reduced 50% by Week 2, sustained through Week 24
Financial Impact
Phase 2 positive data de-risks verekitug for a $495M market cap biotech; potential peak sales if approved could be multi-billion but no guidance provided.
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 results
- Competition from approved biologics (e.g., dupilumab, tezepelumab)
- Company will need additional capital to fund Phase 3; future dilution likely
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $6.55 | awaiting T+60 | — | $2.75 (−58.02%) |
Aug 11, 2026 10w ago | 8-K | $7.44 | awaiting T+60 | — | $2.75 (−63.04%) |
Jun 17, 2026 18w ago | Insider Cluster | $6.25 | awaiting T+60 | — | $2.75 (−56.00%) |
Jun 14, 2026 19w ago | Press Release | $6.10 $5.96 | ▼ −2.30% | ▼ −3.30% | $2.75 (−54.92%) |
May 18, 2026 23w ago | Press Release | $8.51 $6.91 | ▼ −18.80% | ▼ −23.65% | $2.75 (−67.69%) |
May 13, 2026 23w ago | Press Release | $9.36 $7.25 | ▲ +22.54% | ▲ +26.98% | $2.75 (+70.62%) |
Apr 17, 2026 27w ago | Press Release | $9.99 $7.14 | ▼ −28.53% | ▼ −34.67% | $2.75 (−72.47%) |
Mar 26, 2026 30w ago | 424B5 | $8.67 $6.41 | ▲ +26.07% | ▲ +42.13% | $2.75 (+68.28%) |
Mar 26, 2026 30w ago | Press Release | $9.79 $6.40 | ▼ −34.68% | ▼ −48.63% | $2.75 (−71.91%) |
Mar 16, 2026 32w ago | Insider Cluster | $9.61 $6.45 | ▼ −32.88% | ▼ −43.37% | $2.75 (−71.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers